Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION)

V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.

Study ID: 5088
NCT Number: 06909565
Principal Investigator: Albert Chan, MD
Department: Medicine-Cardiology
Eligibility: Both men and women 18 years old to 99 years old. Does not accept healthy volunteers.

For questions about this study, please contact:

ClinicalTrialsInterest@health.missouri.edu
(573) 882-7026